Clinical Significance of Anticardiolipin Antibodies in Patients with Systemic Sclerosis

References

• Medsger T. A., Jr. Systemic sclerosis (scleroderma), eosinophilic fascilitis, and calcinosis. Arthritis and Allied Conditions12th Ed., D. J. McCarty. Lea & Febigcr, Philadelphia 1993; 1253–1292
   Google Scholar
• Norton W. L., Nardo J. M. Vascular disease in progressive systemic sclerosis (scleroderma). Ann. Intern. Med. 1970; 73: 317–324
   PubMed Web of Science ®Google Scholar
• LeRoy E. C., Trojanowska M., Smith E. A. The pathogenesis of scleroderma (systemic sclerosis, SSc). Clin. Exp. Rheumatol. 1991; 9: 173–177
   PubMedGoogle Scholar
• Giordano M., Valentini G., Migliaresi S., Picillo U., Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J. Rheumatol. 1986; 13: 911–916
   PubMed Web of Science ®Google Scholar
• Steen V. D., Powell D. L., Medsger T. A., Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988; 31: 196–203
   PubMed Web of Science ®Google Scholar
• Alarçon-Segovia D., Deleze M., Oria C. V., Sanchez-Guerrero J., Gomez-Pacheco L., Cabiedes J., et al. Antiphospholipid antibodies and antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353–365
   PubMed Web of Science ®Google Scholar
• Lopez L. R., Santos M. E., Espinoza L. R., La Rosa F. G. Clinical significance of immunoglobulin A versus immunoglobulins G and M anticardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia and recurrent abortion. Am. J. Clin. Pathol. 1992; 98: 449–454
   PubMedGoogle Scholar
• Picillo U., Migliaresi S., Marcialis M. R., Longobardo A., La Palombara F., Tirri G. Longitudinal survey of anticardiolipin antibodies in systemic lupus erythematosus. Relationships with clinical manifestations and disease activity in an Italian series. Scand. J. Rheumatol. 1992; 21: 271–276
   PubMed Web of Science ®Google Scholar
• Carreras L. O., Vermylen J. G. “Lupus” anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb. Haemost. 1982; 48: 38–40
   PubMed Web of Science ®Google Scholar
• Tsakiris D. A., Marbet G. A., Makris P. E., Settas L., Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb. Haemost. 1989; 61: 175–177
   PubMedGoogle Scholar
• Khamashta M. A., Harris E. N., Gharavi A. E., Derue G., Gil A., Vazquez J. J., et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann. Rheum. Dis. 1988; 47: 849–854
   PubMed Web of Science ®Google Scholar
• Cosgriff T. M., Martin B. A. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum. 1981; 24: 94–96
   PubMed Web of Science ®Google Scholar
• Sanfelippo M. J., Drayna C. J. Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am. J. Clin. Pathol. 1982; 77: 275–279
   PubMed Web of Science ®Google Scholar
• Cariou R., Tobelem G., Soria C., Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N. Engl. J. Med. 1986; 314: 1193–1194
   PubMed Web of Science ®Google Scholar
• Moreb J., Kitchens C. S. Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: report of 2 cases. Am. J. Med. 1989; 87: 207–210
   PubMed Web of Science ®Google Scholar
• Seibold J. R., Knight P. J., Peter J. B. Anticardiolipin antibodies in systemic sclerosis. Arthritis Rheum. 1986; 29: 1052–1053
   PubMedGoogle Scholar
• Bamberga P., Asero R., Vismara A., Brucato A., Riboldi P., Meroni P. L. Anticardiolipin antibodies in progressive systemic sclerosis (PSS). Clin. Exp. Rheumatol. 1987; 387–388
   PubMedGoogle Scholar
• Malia R. G., Greaves M., Rowlands L. M., Lawrence A. C. K., Hume A., Rowell N. R., et al. Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Gin. exp. Immunol. 1988; 73: 456–460
   PubMed Web of Science ®Google Scholar
• Buchanan R. R. C., Wardlaw J. R., Riglar A. G., Littlejohn G. O., Miller M. H. Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J. Rheumatol. 1989; 16: 757–761
   PubMedGoogle Scholar
• Katayama I., Otoyama K., Kondo S., Nishioka K., Nishiyama S. Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. J. Am. Acad. Dermatol. 1990; 23: 198–201
   PubMedGoogle Scholar
• Passaleva A., Massai G., Matucci-Cerinic M., Domeneghetti M. P., Sharifian J., Lotti T., et al. Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. Autoimmunity 1990; 6: 283–291
   PubMed Web of Science ®Google Scholar
• Lima J., Follonosa V., Fernández-Cortijo J., Ordi J., Cuenca R., Khamashta M. A., et al. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J. Rheumatol. 1991; 18: 1833–1836
   PubMedGoogle Scholar
• Masi A. T., Rodnan G. P., Medsger T. A., Altman R. D., D'Angelo W. A., Fries J. F., et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 25: 581–590
   Google Scholar
• Rodnan G. P., Jablonska S., Medsger T. A. Classification and nomenclature of progressive systemic sclerosis (scleroderma). Clin. Rheum. Dis. 1979; 5: 5–14
   Google Scholar
• Greaves M., Malia R. G., Ward Milford A., Moult J., Holt C. M., Lindsey N., et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br. J. Rheumatol. 1988; 27: 281–285
   PubMedGoogle Scholar
• Furst D. E., Clements P. J., Hillis S., Lachenbruch P. A., Miller B. L., Sterz M. G., et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum. 1989; 32: 584–593
   PubMed Web of Science ®Google Scholar
• Glantz S. A. Primer of biostatistics. McGraw-Hill, New York 1987
   Google Scholar
• Whittaker R., Barnett A., Ryan P. Antiphospholipid syndrome in scleroderma. J. Rheumatol. 1993; 20: 1598–1600
   PubMedGoogle Scholar
• Herrick A. L., Oogarah P., Brammah T. B., Freemont A. J., Jayson M. I. V. Nervous system involvement in association with vasculitis and anticardiolipin antibodies in a patient with systemic sclerosis. Ann. Rheum. Dis. 1994; 53: 349–350
   PubMedGoogle Scholar
• Doria A., Ruffatti A., Calligaro A., Del Ross T., Ghirardello A., De Zambiasi P., et al. Antiphospholipid antibodies in mixed connective tissue disease. Clin. Rheumatol. 1992; 11: 48–50
   PubMedGoogle Scholar
• Miyata M., Kida S., Kanno T., Suzuki K., Watanabe H., Kaise S., et al. Pulmonary hypertension in MCTD: report of two cases with anticardiolipin antibody. Clin. Rheumatol. 1992; 11: 195–201
   PubMedGoogle Scholar
• Keane A., Woods R., Dowding V., Roden D., Barry C. Anticardiolipin antibodies in rheumatoid arthiritis. Br. J. Rheumatol. 1987; 26: 346–350
   PubMedGoogle Scholar
• Hughes G. R. V., Harris E. N., Gharavi A. E. The anticardiolipin syndrome. J. Rheumatol. 1986; 13: 486–489
   PubMed Web of Science ®Google Scholar
• Harris E. N. Syndrome of the black swan. Br. J. Rheumatol. 1987; 26: 324–326
   PubMedGoogle Scholar
• Kahaleh M. B. Vascular disease in scleroderma. Endothelial T lymphocyte-fibroblast interaction. Rheum. Dis. Clin. North. Am. 1990; 16: 53–73
   PubMedGoogle Scholar
• Shapiro L. Large vessel arterial thrombosis in systemic sclerosis associated with antiphospholipid antibodies. J. Rheumatol. 1990; 17: 685–688
   PubMedGoogle Scholar
• Barile L. A., Bravo G., Pizarro S. Large vessel arterial thrombosis in systemic sclerosis with antiphospholipid antibodies. J. Rheumatol. 1990; 17: 1721
   PubMedGoogle Scholar
• Youssef P., Englert H., Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann. Rheum. Dis. 1993; 52: 464–466
   PubMed Web of Science ®Google Scholar
• Kahaleh M. B. The role of vascular cndothelium in the pathogenesis of connective tissue disease: endothelial injury, activation, participation and response. Clin. Exp. Rheumatol. 1990; 8: 595–601
   PubMed Web of Science ®Google Scholar
• Rosembaum J. R., Pottinger B. E., Woo P., Black C M., Byron M. A., Pearson J. S. Measurement and characterization of circulating anti-endothelial cell IgG in connective tissue diseases. Clin. exp. Immunol. 1988; 72: 450–456
   PubMedGoogle Scholar
• Penning C. A., Cunningham J., French M. A. H., Harrison G., Rowell N. R., Hughes P. Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. Clin. exp. Immunol. 1984; 58: 548–556
   PubMedGoogle Scholar
• Marks R. M., Czerniecki M., Andrews B. S., Penny R. The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum. 1988; 31: 1524–1534
   PubMed Web of Science ®Google Scholar
• Beckett V. L., Conn D. L., Fuster V., Osmundson P. J., Strong C. G., Chao E. Y. S., et al. Trial of platelet-inhibiting drug in scleroderma: double-blind study with dipyridamole and aspirin. Arthritis Rheum. 1984; 27: 1137–1143
   PubMedGoogle Scholar